Prostate Cancer
Localised, biochemical relapse, mHSPC, mCRPC
DefinitionClick to collapse
Prostate cancer is a malignancy arising from the epithelial cells of the prostate gland, an exocrine organ of the male reproductive system located posterior to the pubic symphysis and anterior to the rectum. The prostate is embryologically derived from the urogenital sinus, specifically from the endodermal cloaca. Its anatomical boundaries are defined by the bladder neck superiorly, the urogenital diaphragm inferiorly, the seminal vesicles and vas deferens posteriorly, and the rectoprostatic fascia (Denonvilliers' fascia) separating it from the rectum. The prostate is divided into distinct zones: the peripheral zone (where ~70% of adenocarcinomas arise), the central zone, and the transition zone (common site for benign prostatic hyperplasia). The most common histologic type is adenocarcinoma, which typically originates in the peripheral zone. Clinical suspicion arises from an abnormal digital rectal exam (DRE) or an elevated prostate-specific antigen (PSA) level. Definitive diagnosis requires histologic confirmation via prostate biopsy, usually performed under transrectal ultrasound (TRUS) guidance. The pathologic grade is determined using the Gleason grading system, which has been updated to a 5-tier Grade Group system (1-5) based on the Gleason score [1, 2]. Clinical staging follows the American Joint Committee on Cancer (AJCC) TNM system (8th edition), incorporating clinical stage (cT), pathologic stage (pT), lymph node status (N), and metastasis status (M) [3]. Risk stratification for treatment purposes is based on these clinical and pathologic features, including TNM stage, Grade Group, and PSA level, which are used to assign patients to NCCN risk groups (low, favorable intermediate, unfavorable intermediate, high, and very high) [4].
EpidemiologyClick to collapse
SubtypesClick to collapse
Adenocarcinoma
The most common histologic subtype (~95% of cases), typically arising from glandular epithelial cells of the prostate. It is graded using the Gleason system (Grade Groups 1-5) based on architectural patterns.
Ductal Adenocarcinoma
A rare variant (approximately 1.3% of prostate carcinomas) characterized by growth patterns resembling the ducts of the normal prostate. It may exhibit papillary, cribriform, or flat growth patterns.
Intraductal Carcinoma of the Prostate (IDC-P)
A histologic pattern defined by cribriform proliferation of malignant cells confined within preexisting prostatic ducts surrounded by a layer of basal cells. It is frequently associated with invasive carcinoma.
Neuroendocrine Prostate Cancer (NEPC) / Small Cell Carcinoma
A rare and aggressive variant that may arise de novo or, more commonly, as a treatment-emergent differentiation following androgen deprivation therapy. Histology shows small, round, blue cells with neuroendocrine features.
Squamous Cell Carcinoma
A very rare non-adenocarcinoma histologic type characterized by malignant squamous differentiation.
Transitional Cell (Urothelial) Carcinoma
Arises from the urothelium lining the prostatic urethra and ducts. More common in the bladder than in the prostate.
Molecular PathogenesisClick to collapse
Prostate cancer pathogenesis is driven by a complex interplay of genetic, epigenetic, and microenvironmental factors. A hallmark early event is the androgen receptor (AR) signaling pathway, which is critical for tumor growth and survival. Key genomic events include: 1) TMPRSS2-ERG gene fusion (present in ~50% of cases), which places the ERG oncogene under the control of the androgen-responsive TMPRSS2 promoter, leading to aberrant ERG expression [5]. 2) PTEN loss (via deletion or mutation), occurring in ~40-50% of metastatic cases, leads to activation of the PI3K/AKT/mTOR pathway and is associated with aggressive disease [5]. 3) TP53 and RB1 inactivation (more frequent in advanced/metastatic disease), contributing to genomic instability and loss of cell cycle control [5]. 4) AR amplification, mutations, or splicing variants (e.g., AR-V7) drive progression to castration-resistant prostate cancer (CRPC) by maintaining AR signaling despite androgen deprivation [5]. 5) Somatic mutations in DNA repair genes, most notably BRCA1/BRCA2 (germline or somatic), are found in up to 23% of mCRPC tumors and confer sensitivity to PARP inhibitors and platinum chemotherapy [6, 7]. Other frequently mutated genes include ATM, PALB2, FANCA, RAD51D, CHEK2, and CDK12 [6, 7]. 6) Defects in DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2) lead to microsatellite instability-high (MSI-H)/deficient MMR (dMMR) status in a subset of tumors (estimated 2-5%), making them potentially responsive to immune checkpoint inhibitors like pembrolizumab [8]. 7) SPOP mutations are the most common point mutation in primary prostate cancer. 8) MYC amplification and TP53/RB1 loss are associated with neuroendocrine prostate cancer (NEPC) differentiation, a treatment-emergent aggressive phenotype [5]. Chromosomal abnormalities like deletions of 8p (harboring NKX3.1) and gains of 8q (harboring MYC) are common. Epigenetic alterations, including DNA hypermethylation, also play a role in silencing tumor suppressor genes [5].
Risk FactorsClick to collapse
Age
Risk increases dramatically with age. Prostate cancer is rare before age 50, and the majority of cases are diagnosed in men over 65.
Race/Ethnicity
Black men have a 67% higher incidence and significantly higher mortality compared to White men. The reasons are multifactorial, likely involving a combination of genetic, biological, social, and healthcare access factors [11].
Family History
A first-degree relative with prostate cancer increases risk 2- to 3-fold. The risk is higher with multiple affected relatives or a relative diagnosed at a young age (<60 years) [16]. Specific hereditary cancer syndromes, such as Hereditary Breast and Ovarian Cancer (HBOC) syndrome (due to germline BRCA1/2 mutations) and Lynch syndrome, significantly elevate risk [6].
Germline Genetic Mutations
Pathogenic germline mutations in homologous recombination repair (HRR) genes, particularly BRCA2, are associated with a 2- to 6-fold increased risk of prostate cancer and more aggressive disease. Mutations in ATM, PALB2, and CHEK2 also increase risk [6, 17].
Geographic Location
Incidence is highest in North America, Northwestern Europe, Australia, and the Caribbean. It is lower in Asia and Africa, though migrating populations from low-risk areas gradually adopt the higher risk of their new region, suggesting lifestyle and environmental factors.
Diet and Obesity
High consumption of red meat and high-fat dairy products, and low consumption of fruits and vegetables, may be associated with a slightly increased risk. Obesity (high BMI) is linked to a higher risk of aggressive prostate cancer.
Androgen Levels
Higher endogenous androgen levels or androgen receptor activity are thought to promote prostate cancer development.
History of Prostatitis
Some studies suggest a possible association with an increased risk, but evidence is not consistent.
PSA Screening
Widespread use of PSA testing leads to increased detection of prostate cancer (overdiagnosis), including many indolent tumors that might not have caused symptoms or death during a patient's lifetime.
Clinical FeaturesClick to collapse
Typical Presentation
Prostate cancer is often diagnosed following an abnormal digital rectal examination (DRE) or an elevated prostate-specific antigen (PSA) level, frequently discovered during screening or routine evaluation. The initial suspicion of prostate cancer is based on these findings. A definitive diagnosis requires biopsies of the prostate, usually performed by a urologist using a needle under transrectal ultrasound (TRUS) guidance. A pathologist assigns a Gleason primary and secondary grade to the biopsy specimen. Many patients are asymptomatic at the time of diagnosis, particularly those detected through PSA-based screening. Prostate cancer is the most common cancer in men in the United States, with an estimated 313,780 new cases diagnosed in 2025, accounting for 30% of new cancer cases in men. The lifetime risk of developing prostate cancer is 1 in 8. For all stages combined, the 5-year relative survival rate for prostate cancer is 97%. When symptoms do occur, they may include urinary symptoms (difficulty starting or stopping urination, weak or interrupted flow, frequent urination especially at night, difficulty emptying the bladder completely, and burning or pain during urination), bone pain, unexplained weight loss, and fatigue. These symptoms are more common in advanced disease.
Symptoms
Urinary obstruction symptoms
Difficulty starting urination, weak or interrupted urinary stream, frequent urination especially at night (nocturia), difficulty emptying the bladder completely. These may result from local prostate enlargement.
Bone pain
Pain in the back, hips, ribs, or other bones may indicate osseous metastatic disease. Bone metastases are a common site of spread.
Unexplained weight loss
Significant unexplained weight loss may indicate advanced or metastatic disease.
Fatigue
Persistent unexplained fatigue may be associated with advanced disease or bone metastases.
Hematuria
Blood in the urine may occur with locally advanced disease involving the bladder or urethra.
Pathologic fracture
Fractures occurring with minimal trauma in the setting of bone metastases. May be the initial presentation of metastatic disease.
Signs
Abnormal digital rectal examination (DRE)
DRE findings may include a firm or hard nodule in the prostate, asymmetry, or fixed induration suggesting extracapsular extension. The prostate may feel normal in many cases of early-stage disease.
Elevated prostate-specific antigen (PSA)
PSA levels above the age-specific reference ranges. Normal PSA is generally considered <4 ng/mL, though elevated PSA can result from benign conditions (BPH, prostatitis) as well as malignancy.
Elevated PSA density
PSA density (PSA divided by prostate volume) ≥0.15 ng/mL/g is associated with increased probability of clinically significant cancer and higher risk of grade reclassification during active surveillance.
Abnormal multiparametric MRI (mpMRI) findings
mpMRI with PI-RADS scoring can identify suspicious lesions. PI-RADS 4 or 5 lesions have increased risk of biopsy progression during active surveillance.
Red FlagsClick to collapse
Symptoms consistent with bone metastases (bone pain, unexplained weight loss, pathologic fracture) should prompt bone imaging regardless of PSA level
Rapidly rising PSA or short PSA doubling time (PSADT ≤8-10 months) suggesting aggressive disease biology
PSA persistence after radical prostatectomy (PSA does not fall to undetectable levels) indicating residual disease
PSA increase by ≥2 ng/mL above nadir after radiation therapy (Phoenix definition) indicating biochemical recurrence
New neurological symptoms suggesting spinal cord compression from vertebral metastases
Visceral metastases (liver, lung, adrenal gland, peritoneum, brain) indicating more aggressive disease requiring urgent systemic therapy evaluation
Symptomatic skeletal-related events: fractures, spinal cord compression, or need for surgery or radiation to bone
Clinical features of aggressive variant prostate cancer: visceral metastases, low PSA with bulky disease, high lactate dehydrogenase (LDH), high carcinoembryonic antigen (CEA), lytic bone metastases, or neuroendocrine histology
Clinical features suggesting treatment-related small cell/neuroendocrine prostate cancer: disease that no longer responds to ADT with positive metastases, associated with low PSA despite large metastatic burden and visceral disease, especially in patients with initial Grade Group 5
Evidence of castration-resistant progression: clinical, radiographic, or biochemical progression despite castrate levels of serum testosterone (<50 ng/dL)
InvestigationsClick to collapse
Diagnostic
Prostate-specific antigen (PSA) level
Primary screening and monitoring tool for prostate cancer. Elevated PSA is the most common finding leading to diagnosis.
Digital rectal examination (DRE)
Physical examination to assess prostate size, consistency, and clinical stage. Performed to confirm clinical stage.
Prostate biopsy (transrectal ultrasound-guided or MRI-guided)
Definitive diagnostic test required for all patients. Pathologist assigns Gleason primary and secondary grade and Grade Group.
Multiparametric MRI (mpMRI) of the prostate
PI-RADS scoring for risk stratification; helps detect clinically significant cancers (Grade Group ≥2), aids in staging (T-staging for extracapsular extension), and guides targeted biopsy.
Pathology synoptic reports
Comprehensive pathology reporting per College of American Pathologists (CAP) protocols.
Staging
Bone imaging (bone scan or PSMA-PET/CT or PSMA-PET/MRI)
Assess for osseous metastases. Indicated for patients with unfavorable intermediate, high, very-high risk disease (PROS-2), regional disease (PROS-7), and any patient with symptoms consistent with bone metastases.
CT scan (chest, abdomen, pelvis with contrast)
Soft tissue imaging to assess for lymph node metastases, visceral metastases, and extracapsular extension. May be performed with IV contrast.
Abdominopelvic MRI (with and without contrast)
Preferred over CT for pelvic staging in many settings; high soft tissue contrast for assessment of local extension and lymphadenopathy.
PSMA-PET/CT or PSMA-PET/MRI
Whole-body imaging with PSMA tracers (F-18 piflufolastat PSMA, F-18 flotufolastat PSMA, or Ga-68 PSMA-11) can be considered as an alternative to CT, MRI, and bone scans for initial staging of unfavorable intermediate, high, and very-high-risk disease. Higher sensitivity than C-11 choline or F-18 fluciclovine PET, especially at very low PSA levels.
FDG-PET/CT
Not routinely recommended for staging prostate cancer due to limited data. May be prognostic in progressive CRPC. Useful in combination with PSMA-PET for biological heterogeneity assessment.
F-18 fluciclovine PET/CT or C-11 choline PET/CT
Can be used to detect small-volume recurrent disease in soft tissues and bone. Considered for equivocal results on initial bone scan.
F-18 sodium fluoride PET/CT
Targets osteoblast activity; can be considered for equivocal results on initial bone scan. Higher sensitivity than standard bone scan.
Pelvic lymph node dissection (PLND)
Can be performed with radical prostatectomy for staging and prognostic information. Extended PLND provides more complete staging. May cure some patients with microscopic metastases.
Biomarkers
Germline genetic testing
Testing for hereditary cancer syndromes including BRCA1, BRCA2, ATM, CHEK2, and mismatch repair genes. Implications for family risk assessment, other cancer screening, cascade testing for relatives, and potential treatment implications.
Somatic tumor testing for homologous recombination repair (HRR) gene mutations
Testing for mutations in BRCA1, BRCA2, ATM, PALB2, FANCA, RAD51D, CHEK2, CDK12 and other HRR genes. BRCA1/2 and BRCA2 mutations in particular are associated with response to PARP inhibitor therapy.
Tumor testing for MSI-H or dMMR
Microsatellite instability-high or mismatch repair deficient testing. If positive, indicates eligibility for pembrolizumab in mCRPC and warrants referral for genetic counseling to assess for Lynch syndrome.
Tumor mutational burden (TMB) testing
TMB ≥10 mut/mB may indicate potential benefit from pembrolizumab in mCRPC based on limited data.
Plasma circulating tumor DNA (ctDNA) assay
Alternative to metastatic biopsy when biopsy is unsafe or unfeasible. Should preferably be collected during biochemical and/or radiographic progression to maximize diagnostic yield. Caution needed due to potential interference from clonal hematopoiesis of indeterminate potential (CHIP).
PSA density
Calculated as PSA divided by prostate volume. PSADT (PSA doubling time) is important for risk stratification and treatment decisions, particularly in the BCR and CRPC settings.
StagingClick to collapse
AJCC 8th Edition (2017) TNM Staging System for Prostate Cancer. Clinical stage is based on TNM classification. Prognostic stage groups incorporate TNM stage, PSA level, and Grade Group.
T Categories
| Stage | Description |
|---|---|
| Clinical T (cT) | Clinical assessment of primary tumor based on DRE and imaging |
| cTX | Primary tumor cannot be assessed |
| cT0 | No evidence of primary tumor |
| cT1 | Clinically inapparent tumor that is not palpable |
| cT1a | Tumor incidental histologic finding in 5% or less of tissue resected |
| cT1b | Tumor incidental histologic finding in more than 5% of tissue resected |
| cT1c | Tumor identified by needle biopsy found in one or both sides, but not palpable |
| cT2 | Tumor is palpable and confined within prostate |
| cT2a | Tumor involves one-half of one side or less |
| cT2b | Tumor involves more than one-half of one side but not both sides |
| cT2c | Tumor involves both sides |
| cT3 | Extraprostatic tumor that is not fixed or does not invade adjacent structures |
| cT3a | Extraprostatic extension (unilateral or bilateral) |
| cT3b | Tumor invades seminal vesicle(s) |
| cT4 | Tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall |
| Pathological T (pT) | Pathological assessment of primary tumor after surgery. Note: There is no pathological T1 classification. |
| pT2 | Organ confined |
| pT3 | Extraprostatic extension |
| pT3a | Extraprostatic extension (unilateral or bilateral) or microscopic invasion of bladder neck |
| pT3b | Tumor invades seminal vesicle(s) |
| pT4 | Tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall |
N Categories
| Stage | Description |
|---|---|
| NX | Regional lymph nodes cannot be assessed |
| N0 | No positive regional nodes |
| N1 | Metastases in regional node(s) |
M Categories
| Stage | Description |
|---|---|
| M0 | No distant metastasis |
| M1 | Distant metastasis |
| M1a | Nonregional lymph node(s) |
| M1b | Bone(s) |
| M1c | Other site(s) with or without bone disease. Note: When more than one site of metastasis is present, the most advanced category is used. M1c is most advanced. |
Stage Groupings
| Group | Criteria | Clinical Meaning | Five Yr Survival | Treatment Intent |
|---|---|---|---|---|
| Stage I | cT1a-c, N0, M0, PSA <10, Grade Group 1 | Very early, organ-confined, low-grade cancer. Active surveillance preferred. | Near 100% | Curative or observation |
| Stage IIA | cT1a-c, N0, M0, PSA ≥10 to <20, Grade Group 1; OR cT2a, N0, M0, PSA ≥10 to <20, Grade Group 1; OR pT2, N0, M0, PSA ≥10 to <20, Grade Group 1; OR cT2b, N0, M0, PSA <20, Grade Group 1; OR cT2c, N0, M0, PSA <20, Grade Group 1 | Low to intermediate risk; organ confined with low grade or higher stage with very low PSA. | Near 100% | Curative |
| Stage IIB | T1-2, N0, M0, PSA <20, Grade Group 2 | Intermediate risk; Gleason 3+4 pattern. | Excellent | Curative |
| Stage IIC | T1-2, N0, M0, PSA <20, Grade Group 3; OR T1-2, N0, M0, PSA <20, Grade Group 4 | Higher intermediate to high risk with aggressive histology. | Good to excellent depending on specific features | Curative |
| Stage IIIA | T1-2, N0, M0, PSA ≥20, Grade Group 1-4 | Intermediate to high risk based on elevated PSA. | Good | Curative |
| Stage IIIB | T3-4, N0, M0, Any PSA, Grade Group 1-4 | Locally advanced disease with extraprostatic extension or invasion of adjacent structures. | Good with appropriate multimodality therapy | Curative with multimodality approach |
| Stage IIIC | Any T, N0, M0, Any PSA, Grade Group 5 | Very high risk with Gleason 9-10 histology. | Variable; depends on completeness of response to multimodality therapy | Curative with multimodality approach |
| Stage IVA | Any T, N1, M0, Any PSA, Any Grade Group | Regional disease with pelvic lymph node metastases. | Variable; depends on response to systemic therapy | Curative or palliative depending on extent |
| Stage IVB | Any T, Any N, M1, Any PSA, Any Grade Group | Metastatic disease with distant metastases. | Variable; improved with modern systemic therapies | Palliative; systemic therapy with intent to prolong survival |
Staging Pearls
- The NCCN guidelines use NCCN risk group classification (low, favorable intermediate, unfavorable intermediate, high, very high) rather than AJCC prognostic staging groups for treatment recommendations.
- Grade Group system (ISUP 2014): Grade Group 1 = Gleason ≤6; Grade Group 2 = Gleason 3+4=7; Grade Group 3 = Gleason 4+3=7; Grade Group 4 = Gleason 4+4=8 or 3+5=8 or 5+3=8; Grade Group 5 = Gleason 9-10.
- High-volume mCSPC is defined based on CHAARTED criteria: presence of visceral metastases or ≥4 bone lesions with ≥1 beyond the vertebral bodies and pelvis.
- Low-volume mCSPC: defined as not meeting high-volume criteria; may include patients with ≤5 bony metastases without visceral metastases.
- Metachronous oligometastatic disease: metastatic disease detected after prior definitive therapy, distinguishable from synchronous metastatic disease.
- PSA persistence after RP is defined as when PSA does not fall to undetectable levels; PSA recurrence after RP is undetectable PSA after RP with subsequent detectable PSA that increases on ≥2 determinations or increases to PSA >0.1 ng/mL.
- PSA recurrence after radiation (Phoenix definition): PSA increase by ≥2 ng/mL above the nadir PSA.
- CRPC is defined as prostate cancer that progresses clinically, radiographically, or biochemically despite castrate levels of serum testosterone (<50 ng/dL).
- Adverse pathologic features include: positive margin(s), seminal vesicle invasion, or extracapsular extension.
- Small cell neuroendocrine prostate cancer (NEPC) may be present in up to 17% of mCRPC patients; histologic evidence of both adenocarcinoma and small cell carcinoma may be present in the same specimen.
- PSMA-PET imaging should only be used in the setting of M1 CRPC to determine if a patient is a candidate for Lu-177-PSMA-617; changes in systemic therapy should not be made solely based on a positive PSMA-PET in patients with M0 CRPC.
- The Will Rogers phenomenon: improved imaging (such as PSMA-PET) may upstage patients from M0 to M1b, potentially improving outcomes in both groups without any actual change in treatment efficacy.
- When more than one site of metastasis is present, the most advanced M category is used (M1c is most advanced).
- This staging classification applies to adenocarcinomas and squamous carcinomas, but not to sarcoma or transitional cell (urothelial) carcinoma of the prostate.
- Adjectives used to describe histologic variants include mucinous, signet ring cell, ductal, and neuroendocrine, including small cell carcinoma. Histologic confirmation of disease is required.
- Positive surgical margin should be indicated by an R1 descriptor, indicating residual microscopic disease.
- Life expectancy estimation is critical for treatment decisions. The Social Security Administration tables, MSK Male Life Expectancy tool, or UCSF Lee Schonberg Index can be used, adjusted by adding or subtracting 50% based on the patient's overall health quartile.
Management PrinciplesClick to collapse
Prostate cancer treatment is guided by risk stratification using TNM staging, Gleason grade group, and PSA level. The NCCN Panel employs a multimodal approach where treatment decisions are personalized based on disease characteristics, life expectancy, comorbidities, and patient preferences [PROS-1, PROS-2]. Treatment philosophy emphasizes avoiding overtreatment of indolent disease through active surveillance in low-risk patients while ensuring adequate treatment intensification in high-risk and metastatic disease states. All recommendations are category 2A unless otherwise indicated.
Curative
Clinically localized disease (N0, M0) with life expectancy ≥10 years
Active surveillance (preferred for low-risk), radical prostatectomy, or radiation therapy with or without ADT depending on risk group
Curative/Survival-prolonging
Regional disease (N1, M0) or high/very-high-risk localized disease
RT plus long-term ADT (18-36 months), with abiraterone for very-high-risk or N1 disease; or RP plus PLND in select patients
Palliative/Survival-prolonging
Metastatic castration-sensitive prostate cancer (mCSPC)
ADT with treatment intensification using ARPIs and/or docetaxel; MDT for oligometastatic disease
Survival-prolonging/Palliative
Castration-resistant prostate cancer (CRPC)
Sequential systemic therapies based on prior ARPI and docetaxel exposure, including PARP inhibitors for HRRm, Lu-177-PSMA-617, radium-223, and chemotherapy
All patients diagnosed with intermediate-, high-, very-high-, regional-risk, low-volume mCSPC, biochemically recurrent, and oligometastatic mCRPC are recommended to be evaluated by a radiation oncologist as part of a multidisciplinary discussion [PROS-J]. Multidisciplinary tumor board review is essential for complex clinical scenarios including node-positive disease, biochemical recurrence, and metastatic disease where multiple treatment modalities may be considered [PROS-D].
Life expectancy estimation is critical to informed decision-making and is determined using Social Security Administration tables, WHO Life Tables, MSK Male Life Expectancy tool, or UCSF Lee Schonberg Index, adjusted by +50% for best quartile health and -50% for worst quartile health [PROS-A]. For patients with life expectancy ≤5 years with low- and intermediate-risk disease, no imaging or treatment is indicated until symptoms develop. For those with high/very-high risk and life expectancy ≤5 years, observation may be appropriate if asymptomatic, though bone imaging should be performed if symptomatic [PROS-2A footnote j]. ECOG performance status 0-1 is required for sipuleucel-T [PROS-N footnote ppp].
Management PathwaysClick to collapse
Branching: Life expectancy, Patient preference, PSA density, Number of positive cores, Genomic risk, BRCA2 germline mutation status
Branching: Life expectancy, Number of IRFs, Grade Group, Percentage of positive cores, PSA density, Cribriform histology, Intraductal carcinoma
Branching: Number of IRFs, Grade Group, Percentage of positive cores, Life expectancy
Branching: High vs very-high risk, Life expectancy, Symptom status
Branching: Life expectancy, Symptom status
Branching: Life expectancy, Metastatic status, PSADT, Pre-treatment risk, Pathologic features
Branching: Life expectancy, Metastatic status, PSADT, Risk stratification
Branching: Risk stratification (PSADT, PSA level), Metastatic status
Branching: Number of metastatic sites, Metastasis burden on imaging, Treatment response
Branching: Synchronous vs metachronous, BRCA2 mutation status, Fit for chemotherapy
Branching: Synchronous vs metachronous, Fit for chemotherapy, BRCA2 mutation status
Branching: PSADT, Metastatic status on imaging
Branching: Prior ARPI exposure, Prior docetaxel exposure, BRCA mutation status, HRR mutation status, MSI-H/dMMR status, PSMA-positive status, Disease state (oligometastatic, visceral, symptomatic bone)
Branching: Histology confirmation, Disease extent
Pretreatment EvaluationClick to collapse
Initial Workup - Clinically Localized Disease
Risk Stratification and Additional Evaluation
Regional/Metastatic Disease Additional Evaluation
Imaging
Molecular/Biomarker Testing
Pathology
Functional Assessments and Consultations
SurgeryClick to collapse
Radical prostatectomy is an appropriate curative treatment for clinically localized prostate cancer in patients with life expectancy ≥10 years without serious comorbidities contraindicating elective surgery. RP is also an option for highly selected patients with local recurrence after EBRT, brachytherapy, or cryotherapy. RP should be viewed as one component of a multimodality approach for high-risk disease [PROS-K].
RP is appropriate for any patient not on active surveillance with clinically localized prostate cancer that can be completely excised, life expectancy ≥10 years, and no serious comorbidities [PROS-K]
High-volume surgeons in high-volume centers generally provide better outcomes [PROS-K]
Blood loss can be reduced by laparoscopic or robotic assistance [PROS-K]
Urinary incontinence reduced by preserving urethral length beyond apex and avoiding distal sphincter damage; bladder neck preservation may decrease incontinence risk [PROS-K]
Erectile function recovery related to age, preoperative function, and degree of cavernous nerve preservation; nerve grafts not shown beneficial [PROS-K]
Extended PLND recommended when PLND is performed, including removal of node-bearing tissue bounded by external iliac vein, pelvic sidewall, bladder wall, pelvis floor, Cooper's ligament, and internal iliac artery [PROS-K]
RP + PLND can be considered in favorable intermediate through very-high risk; recommended in unfavorable intermediate, high, very-high, and regional disease [PROS-K]
Procedures
Radical Prostatectomy
Clinically localized prostate cancer (N0, M0) with life expectancy ≥10 years; RP should be viewed as one component of multimodality approach for high-risk disease; select patients with N1 disease with >10-year life expectancy and resectable disease [PROS-7A, PROS-K]
Pelvic Lymph Node Dissection (PLND)
Recommended in unfavorable intermediate, high, very-high, and regional prostate cancer. Can be considered in favorable intermediate-risk. Extended PLND recommended when performed [PROS-K]
Secondary Radical Prostatectomy
Highly selected patients with local recurrence after EBRT, brachytherapy, or cryotherapy without metastatic disease; morbidity high (incontinence, loss of erection, anastomotic stricture, rectal injury) [PROS-K]
Radiation TherapyClick to collapse
Radiation therapy (RT) is a primary treatment option for clinically localized prostate cancer across all risk groups. RT is also used in combination with ADT for regional (N1M0) disease, in the post-prostatectomy setting for adverse features or biochemical recurrence, for metastasis-directed therapy, and as palliative treatment. IMRT is recommended over 3D conformal RT. Image guidance is encouraged and may include CBCT or MRI [PROS-J].
Principles
- IMRT recommended over 3D conformal RT to improve dose conformality [PROS-J]
- Image guidance with daily 3D imaging (CBCT or MRI) recommended; devices for motion management (fiducials, endorectal balloons) encouraged [PROS-J]
- Photon and proton RT are acceptable and appear to have similar outcomes; potential financial toxicity should be discussed [PROS-J]
- Conventionally fractionated RT is no longer preferred for localized prostate cancer; moderate hypofractionation and ultra-hypofractionation are noninferior [PROS-J]
- SBRT preferred specifically for MDRT, oligoprogression, re-irradiation, and at physician discretion for more durable pain control [PROS-J]
- Biocompatible perirectal spacers may be implanted to reduce rectal dose; patients with gross posterior extraprostatic extension should NOT undergo spacer implantation [PROS-J]
Dose Frameworks
| Name | Total Dose | Dose Per Fraction | Fractions | Schedule | Indication |
|---|---|---|---|---|---|
| Moderate Hypofractionation (Preferred) | 60 Gy | 3 Gy | 20 | Daily over 4 weeks | Preferred for low, FIR, UIR, high, very-high risk localized disease; also used for sRT and post-adjuvant settings |
| Moderate Hypofractionation Alternative | 70.2 Gy | 2.7 Gy | 26 | Daily over 5-6 weeks | Alternative moderate hypofractionation |
| SBRT | 35-40 Gy | 7-8 Gy | 5 | Daily or every other day over 1-2 weeks | Localized prostate (UIR, high-risk with caution); MDRT; oligoprogressive disease |
| Ultra-Hypofractionation (SBRT-adjacent) | 36-38 Gy | 9.5 Gy | 4 | Daily over 1-2 weeks | Localized prostate with image guidance expertise |
| Conventional Fractionation | 78-81.2 Gy | 1.8-2.0 Gy | 39-45 | Daily over 8-9 weeks | Less preferred but acceptable; no longer preferred for localized disease |
| SRT After RP (Moderate Hypofractionation) | 52.5 Gy | 2.625 Gy | 20 | Daily over 4 weeks | Post-prostatectomy secondary RT |
| SRT After RP (Conventional) | 64-70.2 Gy | 1.8-2.2 Gy | 32-39 | Daily over 6-8 weeks | Post-prostatectomy secondary RT |
| Palliative RT | 8 Gy | 8 Gy | 1 | Single fraction | Bone metastases pain palliation; equivalent to longer courses for short-term pain control but higher re-treatment rates |
| Palliative RT (Alternative) | 30 Gy | 3 Gy | 10 | Daily over 2 weeks | Alternative palliative bone metastases dosing |
Approaches
| Name | Dose Fractionation | Concurrent Chemotherapy | Indication | Key Trial | Toxicities |
|---|---|---|---|---|---|
| EBRT for Low-Risk Disease | Moderate hypofractionation (60 Gy in 20 fx) or SBRT (35-40 Gy in 5 fx) preferred | None; ADT not recommended | Low-risk disease if treatment elected (active surveillance preferred) | N/A - monotherapy without ADT | GI: bowel symptoms; GU: urinary symptoms; Sexual: erectile dysfunction |
| EBRT + Short-Term ADT for Unfavorable Intermediate-Risk | Moderate hypofractionation or SBRT | ST-ADT (4-6 months) concurrent/adjuvant; NOT with neoadjuvant | Unfavorable intermediate-risk localized prostate cancer | RTOG 9408, RTOG 0815, MARCAP meta-analysis | ADT-related: hot flashes, fatigue, sexual dysfunction, bone loss, metabolic changes; RT-related: GI and GU toxicity |
| EBRT + Long-Term ADT for High/Very-High Risk | Moderate hypofractionation; SBRT may be considered | LT-ADT (12-36 months); for high-risk with brachytherapy boost, 12 months may be considered | High-risk or very-high-risk localized prostate cancer | EORTC 22961, DART01/05, MARCAP meta-analysis, ASCENDE-RT | ADT-related: hot flashes, fatigue, sexual dysfunction, bone loss, metabolic changes, cardiovascular risk; RT-related: GI and GU toxicity; Brachytherapy boost: higher GU toxicity (grade 3: 18.4% at 5 years) |
| EBRT + ADT + Abiraterone for N1 Disease | EBRT including prostate, seminal vesicles, and pelvic lymph nodes; simultaneous integrated boost to involved nodes | ADT (24 months) + abiraterone preferred | Regional disease (N1M0) | STAMPEDE | Combined ADT, abiraterone, and RT toxicities; grade 3-5 AE with abiraterone: 47% vs 33% (STAMPEDE) |
| EBRT for Synchronous Low-Volume M1 Disease | EBRT to primary tumor (55 Gy in 20 fx or 36 Gy in 6 weekly fx) | ADT ± docetaxel ± abiraterone | Low-volume synchronous mCSPC (non-regional lymph-node-only OR <4 bone metastases without visceral disease) | STAMPEDE (OS benefit in low-volume: HR 0.68), PEACE-1 | Reduced severe genitourinary adverse events with RT to primary (PEACE-1) |
| Brachytherapy Monotherapy | LDR: I-125 145 Gy, Pd-103 125 Gy, Cs-131 115 Gy permanent seed implant; HDR: Ir-192 13.5 Gy x 2 implants or 9.5 Gy BID x 2 implants | None | Low-risk, FIR, carefully selected UIR localized disease | NRG/RTOG 0232 (brachytherapy alone vs brachytherapy + EBRT for intermediate risk) | Urinary frequency, urgency, rectal pain; erectile dysfunction lower with HDR than LDR |
| EBRT + Brachytherapy Boost | EBRT 45-50.4 Gy in 25-28 fx OR 37.5 Gy in 15 fx + LDR boost (I-125: 110-115 Gy, Pd-103: 90-100 Gy, Cs-131: 85 Gy) or HDR boost (Ir-192: 15 Gy x 1 fx or 10.75 Gy x 2 fx) | ADT (12 months or longer) | UIR, high-risk, carefully selected very-high-risk localized disease | ASCENDE-RT (improved bPFS with LDR boost: 86% vs 75% at 7 years; higher GU toxicity) | Increased grade 3 GU events (18.4% at 5 years); increased GI toxicity trend (8.1% vs 3.2% at 5 years) |
| Radiation for Bone Metastases (MDT/SBRT) | SBRT: 9-10 Gy x 3 fx, 12 Gy x 2 fx, 16-24 Gy x 1 fx; or moderate hypofractionation 6.2-6.4 Gy x 5 fx | Concurrent systemic therapy (ADT+ARPI for mCSPC; mCRPC systemic therapy) | Metastasis-directed therapy for oligometastatic CSPC and mCRPC; palliative RT for painful bone metastases | ORIOLE, STOMP, EXTEND, RADIOSA (CSPC); ARTO, GROUQ-PCS-9 (mCRPC) | Generally well-tolerated with SBRT; rare toxicities based on treatment site |
| SRT with ADT After RP | 52.5 Gy in 20 fx (moderate hypofractionation preferred) or 64-70.2 Gy in 32-39 fx | ST-ADT (6 months) generally recommended; LT-ADT for late sRT, multiple adverse features, or N1 disease | PSA persistence/recurrence after RP without M1 disease; early sRT at PSA 0.1-0.2 ng/mL recommended | RADICALS-RT, RTOG 9601, GETUG-AFU 16, RADICALS-HD, SPPORT, DADSPORT meta-analysis | Genitourinary and gastrointestinal toxicity; urinary incontinence and urethral strictures more frequent with adjuvant therapy |
Systemic TherapyClick to collapse
Systemic therapy options for prostate cancer include androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, immunotherapy, PARP inhibitors, radiopharmaceuticals, and targeted agents. ADT forms the backbone of treatment for metastatic and recurrent disease. Treatment intensification with ARPIs and/or docetaxel is strongly recommended for mCSPC. For mCRPC, treatment options are organized by prior ARPI and docetaxel exposure. Biomarker-directed therapy (PARP inhibitors for HRR mutations, pembrolizumab for MSI-H/dMMR) and radiopharmaceuticals (Lu-177-PSMA-617, radium-223) have expanded the therapeutic landscape. FDA-approved biosimilar agents are appropriate substitutes for recommended biologic therapies [PROS-N].
Key Regimens
Treatment Response AssessmentClick to collapse
Title
Monitoring and Treatment Response Assessment
Timing
After initial definitive therapy: PSA every 6-12 months for 5 years, then annually. PSA as frequently as every 3 months may be needed for high-risk patients. After definitive RT: consider DRE if suspicion of recurrence [PROS-8].
Response Logic
-
PSA recurrence after RP: defined as PSA that does not fall to undetectable (persistence) or undetectable PSA followed by detectable PSA increasing on ≥2 determinations or PSA >0.1 ng/mL [PROS-8A footnote w]
-
PSA recurrence after RT: PSA increase ≥2 ng/mL above nadir (Phoenix definition); recurrence evaluation considered when PSA confirmed increasing even if <2 ng/mL above nadir, especially for young/healthy candidates for secondary therapy [PROS-8A footnote v]
-
PSADT calculation required to inform nomogram use and counseling [PROS-10A footnote mm]
-
Document castrate levels of testosterone (<50 ng/dL) if progression occurs on ADT; workup for progression should include bone and soft tissue evaluation [PROS-8A footnote ff]
-
Increasing PSA should NOT be used as sole criteria for progression in mCRPC; assessment should incorporate clinical and radiographic criteria [PROS-N]
Imaging Recommendations
-
PSA every 6-12 months for 5 years after initial definitive therapy, then annually [PROS-8]
-
For post-RP patients: imaging for symptoms or increasing PSA; bone scan rarely positive at PSA <10 ng/mL; PSMA-PET may detect disease at PSA 0.2-0.5 ng/mL [PROS-9]
-
For N1M0 on ADT: physical exam + PSA every 3-6 months; imaging for symptoms or increasing PSA [PROS-8]
-
For localized disease on observation: same monitoring as N1M0 on ADT [PROS-8]
-
Bone scans should be performed for symptoms and as often as every 6-12 months to monitor ADT; in CRPC, 8-12 week intervals appear reasonable [PROS-E]
-
Imaging for progressive CRPC should include chest CT, bone imaging, and abdomen/pelvis CT with contrast or MRI [PROS-E]
-
New lesions on bone scan in setting of falling PSA or soft tissue response may indicate bone scan flare; confirmatory bone scan 8-12 weeks later warranted [PROS-E]
-
PSMA-PET imaging should only be used in M1 CRPC setting to determine candidacy for Lu-177-PSMA-617; changes in systemic therapy should NOT be made solely based on positive PSMA-PET in M0 CRPC [PROS-E]
Biopsy Or Salvage Logic
-
Prostate bed biopsy can be considered in patients with PSA persistence/recurrence after RP if life expectancy >5 years and considering local therapy [PROS-9]
-
Prostate/seminal vesicle biopsy should be considered after RT if local recurrence suspected and staging workup does not reveal metastatic disease [PROS-10]
-
Metastatic biopsy strongly recommended for histologic and molecular evaluation in mCRPC; plasma ctDNA assay if biopsy unsafe/unfeasible [PROS-C, PROS-17]
-
Biopsy should be performed to confirm residual/recurrent prostate cancer after focal ablative therapy [PROS-I]
-
Rapid PSA increase may warrant evaluation (prostate biopsy) prior to meeting Phoenix definition, especially in younger/healthy patients [PROS-8A footnote v]
SurveillanceClick to collapse
Clinical Follow Up Schedule
| Setting | Schedule |
|---|---|
| Post-definitive therapy (RP or RT) - first 5 years | PSA every 6-12 months; consider DRE if suspicion of recurrence |
| Post-definitive therapy - after 5 years | PSA annually; consider DRE if suspicion of recurrence |
| High-risk patients for recurrence | PSA as frequently as every 3 months may be necessary to clarify disease status |
| N1M0 on ADT | Physical examination + PSA every 3-6 months; imaging for symptoms or increasing PSA |
| Localized disease on observation | Physical examination + PSA every 3-6 months; imaging for symptoms or increasing PSA |
| Active surveillance - low risk | PSA no more often than every 6 months; DRE no more often than every 12 months; repeat prostate biopsy no more often than every 12 months; repeat mpMRI no more than every 12 months |
| Active surveillance - favorable intermediate risk | Same as low risk but with greater intensity of monitoring; confirmatory prostate biopsy within 1-2 years of diagnostic biopsy; consider earlier repeat biopsy within 6-12 months if initial biopsy was not mpMRI-guided |
| M0 CRPC | Monitoring with physical exam, PSA every 3-6 months, and imaging for symptoms or increasing PSA; document castrate levels of testosterone |
| M1 CRPC or mCSPC on systemic therapy | Physical examination + PSA every 3-6 months; periodic imaging to monitor treatment response; in CRPC, 8-12 week imaging intervals appear reasonable |
Imaging Strategy
| Setting | Imaging |
|---|---|
| Low-risk localized disease | No routine imaging recommended; bone and soft tissue imaging not indicated for asymptomatic patients with PSA <10 ng/mL |
| Unfavorable intermediate-risk, high-risk, very-high-risk localized disease | Bone and soft tissue imaging recommended; PSMA-PET/CT or PSMA-PET/MRI can be considered as alternative to CT, MRI, and bone scans; mpMRI preferred over CT for pelvic staging |
| Post-RP PSA persistence/recurrence | Bone and soft tissue imaging for life expectancy >5 years; PSMA-PET/CT has increased sensitivity at low PSA levels; bone scans rarely positive in asymptomatic patients with PSA <10 ng/mL |
| Post-RT recurrence | PSADT calculation, bone and soft tissue imaging, consideration of prostate/seminal vesicle biopsy if local recurrence suspected |
| Metastatic disease monitoring | Bone scans and soft tissue imaging obtained regularly during systemic therapy; bone scans as often as every 6-12 months for ADT monitoring; 8-12 week imaging intervals in CRPC |
| M1 CRPC treatment selection | PSMA-PET imaging should only be used to determine if patient is a candidate for Lu-177-PSMA-617; changes in systemic therapy should not be made solely based on positive PSMA-PET in M0 CRPC |
Laboratory Monitoring
- PSA: cornerstone of monitoring; frequency depends on disease state and risk of recurrence
- PSA doubling time: calculated to inform nomogram use and counseling; relative risk for bone metastasis or death increases as PSADT shortens
- Testosterone levels: document castrate levels (<50 ng/dL) if progression occurs on ADT; monitor testosterone 12 weeks after first dose of LHRH therapy then upon increase in PSA
- Serum calcium and creatinine: required prior to denosumab and zoledronic acid therapy; periodic monitoring with denosumab use
- Vitamin D levels: recommended baseline assessment and monitoring during antiresorptive therapy
- Liver function: monthly monitoring during abiraterone therapy
- Potassium and phosphate: monthly monitoring during abiraterone therapy
- Complete blood count: regular monitoring during chemotherapy and PARP inhibitor therapy
- Hepatic and renal function: monitoring during olaparib and rucaparib therapy with dose adjustments as needed
Supportive Follow Up
- DEXA scan before starting ADT and every 1-2 years while on ADT or antiresorptive therapy
- Fracture risk assessment using FRAX annually for all patients on ADT or remaining hypogonadal
- Cardiovascular risk assessment and management of modifiable risk factors
- Geriatric assessment consideration for older adults
- NCCN Distress Thermometer and Problem List utilization including social determinants of health
- Patient-reported outcomes assessment using validated instruments (e.g., EPIC-26)
- Comprehensive dental evaluation before initiating osteoclast inhibitor therapy
- Baseline DEXA and follow-up DEXA after 1 year of antiresorptive therapy
- Consideration of intermittent ADT to reduce toxicity when appropriate
ComplicationsClick to collapse
Disease-Related
| Complication | Management |
|---|---|
| Bone metastases and skeletal-related events | Denosumab 120 mg SQ every 4 weeks (category 1, preferred) or zoledronic acid 4 mg IV every 12 weeks for prevention of symptomatic SREs in patients with bone-metastatic CRPC. EBRT for palliation of painful bone metastases. Radium-223 for symptomatic bone metastases without visceral metastases. Bisphosphonates or denosumab for bone loss prevention in castration-sensitive patients on ADT based on FRAX risk assessment. |
| Spinal cord compression | Emergency MRI for suspected spinal cord compression; emergent decompressive surgery if feasible followed by RT, or RT alone. EBRT can be considered for patients with limited life expectancy. |
| Pathologic fracture | Surgical fixation as needed; antiresorptive therapy with denosumab or zoledronic acid for prevention; calcium and vitamin D supplementation; evaluation of fall risk; weight-bearing exercises. |
| Urinary obstruction | TURP for bladder outlet obstruction; nephrostomy tubes or ureteral stents for ureteral obstruction; palliative RT to prostate if appropriate. |
| Visceral metastases (liver, lung, adrenal, brain) | Systemic therapy based on prior treatments and biomarker status; palliative RT for symptom control; chemotherapy with platinum-based regimens if neuroendocrine features present. |
| Local recurrence after definitive therapy | PSA monitoring per post-treatment protocols; secondary therapy options include RT (for post-RP recurrence), local secondary therapy including cryotherapy, HIFU, IRE, reirradiation, or RP (for post-RT recurrence); systemic therapy if metastatic disease present. |
| Progression to neuroendocrine/small cell prostate cancer | Biopsy of metastatic lesions to identify small cell/neuroendocrine histology; cytotoxic chemotherapy with cisplatin/etoposide, carboplatin/etoposide, docetaxel/carboplatin, or cabazitaxel/carboplatin; consult NCCN Guidelines for Small Cell Lung Cancer for additional options. |
Supportive CareClick to collapse
Supportive care is an integral component of prostate cancer management throughout the disease continuum. The NCCN Guidelines for Survivorship provide comprehensive recommendations regarding common consequences of cancer and cancer treatment, including anxiety, depression, trauma, distress, hormone-related symptoms, sexual dysfunction, and promotion of physical activity, weight management, and immunizations. Shared decision-making incorporating quality-of-life assessments using validated instruments (e.g., EPIC-26) is essential. Geriatric assessment should be considered for older adults. The NCCN Distress Thermometer and Problem List, which includes social determinants of health, should be utilized.
Calcium supplementation of 1000-1200 mg daily from food with supplements if intake is insufficient is recommended for all patients receiving ADT. Vitamin D3 supplementation to maintain serum levels of 30-50 ng/mL is recommended. Nutritional assessment should be performed as part of comprehensive care, particularly for patients experiencing weight loss, anorexia, or treatment-related gastrointestinal side effects.
For chemotherapy-related nausea and vomiting, antiemetic prophylaxis should follow current ASCO/ONS antiemetic guidelines. For abiraterone/prednisone therapy, antiemetics are generally not routinely required. Dexamethasone-based regimens (e.g., with docetaxel) provide inherent antiemetic protection. Supportive antiemetic agents should be provided for patients receiving taxane-based chemotherapy.
Growth factor support should follow NCCN Guidelines for Hematopoietic Growth Factors based on risk of neutropenic fever. Prophylactic G-CSF is recommended for patients ≥65 years receiving biweekly cabazitaxel at 16 mg/m2 dose. The use of myeloid growth factors should follow risk assessment for each chemotherapy regimen. For docetaxel every 3 weeks, G-CSF should be considered based on individual patient risk factors.
Venous thromboembolism prophylaxis should be considered for patients receiving PARP inhibitors, particularly those with additional risk factors. ADT is associated with increased risk of ischemic and thrombotic events, and patients should be monitored for these complications. Patients with prior VTE history on PARP inhibitor therapy warrant close monitoring and may require prophylactic anticoagulation.
Pain management follows NCCN Guidelines for Adult Cancer Pain. Options include pharmacologic management (NSAIDs, opioids, adjuvant analgesics), RT for painful bone metastases (8 Gy x 1 fraction is as effective as longer courses for short-term palliation), and interventional procedures. Radium-223 improves time to pain progression in patients with bone-metastatic CRPC without visceral metastases. Bone antiresorptive therapy with denosumab or zoledronic acid reduces skeletal-related events.
Patient-reported outcomes should be measured using standardized instruments such as EPIC-26 for urinary, bowel, and sexual function assessment. Shared decision-making in a multidisciplinary manner should include explanation of potential benefits and harms of each option. The NCCN Distress Thermometer and Problem List should be used to assess and address distress, including social determinants of health. Studies indicate that patient anxiety during active surveillance is closely linked with provider education on safety of active surveillance.
A comprehensive dental evaluation is recommended for all patients before initiating an osteoclast inhibitor (bisphosphonate or denosumab) to prevent osteonecrosis of the jaw. If invasive dental procedures are required, bone-targeted therapy should be withheld until the dentist confirms complete healing from all dental procedures. Oral hygiene, baseline dental evaluation, and avoidance of invasive dental surgery during therapy are recommended to reduce ONJ risk. Stopping denosumab represents a dilemma as discontinuation can result in rebound bone loss and fractures.
PrognosisClick to collapse
For all stages combined, the 5-year relative survival rate for prostate cancer is 97% [1]. The comparatively low death rate suggests that increased public awareness with earlier detection and treatment has affected mortality from this prevalent cancer, but is also complicated by screening-related lead-time bias and detection of indolent cancers. Researchers estimate that prostate cancer will account for 11% of male cancer deaths in the United States in 2025, with an estimated 35,770 deaths [1]. The age-adjusted death rate from prostate cancer declined by 52% from 1993 to 2017, but the death rate has become more stable in recent years, with a 0.5% annual decrease from 2012 through 2022 [1]. Large inequities exist in incidence and mortality: the incidence rate in Black individuals is 67% higher than in white individuals, and the mortality rate is two to four times higher than all other racial and ethnic groups [11]. However, overall prognosis by race appears similar when patients are treated with the same guideline-concordant care [12].
By Stage
| Stage | Five Yr Survival | Context |
|---|---|---|
| AJCC Stage I | Approximately 100% | Very low risk of prostate cancer-specific mortality; active surveillance is preferred for most patients with low-risk disease and life expectancy ≥10 years |
| AJCC Stage IIA | Approximately 100% | Low risk; active surveillance preferred, though definitive local therapy with RT or RP is appropriate for those with longer life expectancy desiring treatment |
| AJCC Stage IIB | Approximately 100% | Favorable intermediate-risk disease; active surveillance may be considered for select patients; RT without ADT or RP appropriate options |
| AJCC Stage IIC | Approximately 100% | Unfavorable intermediate-risk disease; RT with short-term ADT (4-6 months) or RP are recommended; active surveillance not recommended for patients with life expectancy >10 years |
| AJCC Stage IIIA | Approximately 96% | High-risk disease; RT with long-term ADT (18-36 months) or RP plus PLND; active surveillance not recommended |
| AJCC Stage IIIB | Approximately 93% | High-risk disease with extraprostatic extension; RT with long-term ADT or multi-modality approach including RP in select patients |
| AJCC Stage IIIC | Approximately 93% | Very-high-risk disease (Grade Group 5); RT with long-term ADT (18-36 months); addition of abiraterone for select very-high-risk patients |
| AJCC Stage IVA (N1M0) | Approximately 70-80% | Regional disease; RT with long-term ADT plus abiraterone (preferred), or ADT alone plus abiraterone; 5-year survival significantly lower than localized disease |
| AJCC Stage IVB (M1) | Approximately 31% | Metastatic disease; ADT with treatment intensification strongly recommended; low-volume synchronous oligometastatic disease may benefit from EBRT to primary tumor; prognosis varies significantly by volume and site of metastases |
Prognostic Factors
- NCCN risk group stratification based on T stage, Grade Group (Gleason score), and PSA level
- PSA doubling time (PSADT): shorter PSADT (<12 months) associated with higher risk of progression and death from prostate cancer
- Volume of metastatic disease (CHAARTED criteria: high-volume defined by visceral metastasis or ≥4 bone lesions with ≥1 beyond vertebral bodies and pelvis)
- Gleason grade and pattern 4 percentage: Grade Group 3 (4+3) has higher risk than Grade Group 2 (3+4)
- Intraductal and cribriform histology: associated with poor prognosis and increased risk of metastases
- Germline mutations (BRCA2, ATM, CHEK2): associated with more aggressive phenotype and significantly reduced survival times
- Age and comorbidities: affect life expectancy estimation and treatment recommendation
- PSA density, number of positive cores, and percentage of positive cores
- Adverse pathologic features (post-surgical): positive margins, seminal vesicle invasion, extracapsular extension
- 22-gene genomic classifier (Decipher): independently prognostic for distant metastasis, prostate cancer-specific mortality, and overall survival in multiple randomized trials
- Multimodal AI (MMAI) biomarker: independently prognostic for distant metastasis, PCSM, and death after DM in high- and very-high-risk disease
- Race/ethnicity: Black individuals have higher incidence and mortality, though outcomes appear similar with equitable treatment
Follow UpClick to collapse
Post Curative Treatment
For patients initially treated with curative intent, serum PSA levels should be measured every 6 to 12 months for the first 5 years and then annually [PROS-8]. PSA testing every 3 months may be necessary to clarify disease status, especially in patients at high risk of recurrence [PROS-8A footnote ee]. When prostate cancer recurred after radical prostatectomy, Pound and colleagues found that 45% of patients experienced recurrence within the first 2 years, 77% within the first 5 years, and 96% by 10 years [431]. Post-RP PSA persistence/recurrence is defined as when PSA does not fall to undetectable levels (persistence) or undetectable PSA after RP with a subsequent detectable PSA that increases on ≥2 determinations or increases to PSA >0.1 ng/mL [PROS-9A]. Post-RT biochemical recurrence is defined per the Phoenix Consensus as PSA increase by ≥2 ng/mL above the nadir PSA, or a confirmed increasing PSA after radiation even if the increase above nadir is <2 ng/mL [PROS-7A footnote v].
Surveillance Rationale
The rationale for surveillance after definitive therapy is to detect recurrence at the earliest possible time when secondary treatment is most likely to be effective. Early secondary treatment (at a PSA of 0.1-0.2 ng/mL) is recommended for most patients who experience a biochemical recurrence after RP, as it is associated with decreased all-cause mortality and increased prostate cancer-specific survival [451,452]. The utility of imaging for patients with early PSA persistence/recurrence after RP depends on risk group prior to operation, pathologic Gleason grade and stage, PSA, and PSADT after recurrence. PSMA-PET/CT has increased sensitivity at low PSA levels post-RP, with approximately 30-40% of patients having detectable disease at PSA levels of 0.2 to 0.5 ng/mL.
Late Effects Screening
- Bone health: DEXA scan before starting ADT in patients at increased risk based on FRAX screening; repeat DEXA every 1-2 years while on ADT or antiresorptive therapy; fracture risk assessment using FRAX annually
- Cardiovascular disease: assessment for pre-existing and emerging CVD; risk factor management including hypertension, hyperlipidemia, diabetes, obesity; screening for diabetes and cardiovascular disease for patients receiving ADT
- Metabolic effects of ADT: monitoring for obesity, insulin resistance, lipid alterations, diabetes
- Cognitive function: monitoring for cognitive effects, particularly with second-generation ARPIs
- Psychosocial: assessment for depression, anxiety, erectile dysfunction-related psychological effects
- Urinary and sexual function: ongoing assessment using validated patient-reported outcomes instruments
- Gonadal function recovery: monitoring of testosterone levels after ADT cessation
Recurrence Patterns
PSA recurrence after RP typically occurs within the first 5 years in the majority of patients (77%), with 96% experiencing recurrence by 10 years. The pattern of recurrence is influenced by initial disease risk: patients with lower risk have later and slower recurrences. PSADT is a critical prognostic factor; shorter PSADT (<12 months) indicates more aggressive disease and higher risk of metastatic progression. Local recurrence after RT is most responsive to additional therapy when PSA levels at the time of treatment are low (<5 ng/mL). Bone scan flare is common particularly on initiation of new hormonal therapy, and may be observed in nearly half of patients treated with enzalutamide and abiraterone.
Key TrialsClick to collapse
| Acronym | Full Name | Year | N | Intervention | Comparator | Population | Primary Endpoint | Key Result | Secondary Outcomes | Practice Change | Journal |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LATITUDE | Abiraterone acetate plus prednisone in metastatic castration-sensitive prostate cancer | 2017 | 1199 | Abiraterone + prednisone + ADT | Placebo + prednisone + ADT | High-risk mCSPC (≥2 of: Gleason score 8-10, ≥3 bone metastases, visceral metastases) | Overall survival | OS significantly improved (HR, 0.62; P < .0001). Final OS: median 53.3 vs 36.5 months (HR, 0.66; P < .0001) | Delayed castration-resistant progression (14.8 vs 33.2 months), PSA progression, time to pain progression, chemotherapy initiation all improved | Established abiraterone as standard component of first-line therapy for high-risk mCSPC | N Engl J Med |
| STAMPEDE | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | 2017 | 1917 | ADT + abiraterone + prednisolone | ADT alone | M1 CSPC, N1M0, and high-risk M0 disease | Overall survival | OS improved (HR, 0.63; P < .0001) in overall population; benefit seen across M1, N1, and M0 subsets | FFS improved (HR, 0.29; P < .0001); benefit in survival larger in patients <70 years than ≥70 years | Established abiraterone as standard for newly diagnosed mCSPC and high-risk node-positive/non-metastatic disease | Lancet |
| TITAN | Apalutamide for metastatic, castration-sensitive prostate cancer | 2019 | 1052 | Apalutamide 240 mg/day + ADT | Placebo + ADT | mCSPC | Radiographic PFS and OS | rPFS: HR, 0.48 (P < .001); OS: HR, 0.65 (P < .001) at final analysis with median follow-up 44 months | Time to CRPC, time to pain progression, time to chemotherapy all delayed; QOL maintained | Established apalutamide as category 1 option for mCSPC | N Engl J Med |
| ENZAMET | Enzalutamide with standard first-line therapy in metastatic prostate cancer | 2019 | 1125 | Enzalutamide 160 mg/day + ADT | First-generation antiandrogen + ADT | mCSPC | Overall survival | OS: HR, 0.67 (P = .002) at 34-month follow-up; HR, 0.70 at 68-month follow-up (P < .0001) | PFS using PSA levels and clinical PFS improved | Established enzalutamide as category 1 option for mCSPC | N Engl J Med |
| ARCHES | Randomized phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer | 2019 | 1150 | Enzalutamide 160 mg/day + ADT | Placebo + ADT | mCSPC | Radiographic PFS | rPFS: HR, 0.39 (P < .001); OS: HR, 0.66 (P < .001); ~32% of placebo patients crossed over to enzalutamide | Time to PSA progression, time to new antineoplastic therapy, time to deterioration of QOL all improved | Confirmed enzalutamide benefit in mCSPC | J Clin Oncol |
| PEACE-1 | Abiraterone acetate and prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer | 2022 | 1173 | ADT + docetaxel + abiraterone ± RT | ADT + docetaxel ± RT | De novo mCSPC | Radiographic PFS and OS | rPFS improved with abiraterone (HR, 0.54; P < .0001); OS improved (HR, 0.82; P = .030) in docetaxel-receiving patients | Time to CRPC, time to pain progression delayed; RT to primary tumor benefits only seen with abiraterone | Established triplet therapy (ADT + docetaxel + abiraterone) as category 1 option for high-volume mCSPC | Lancet |
| ARASENS | Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer | 2022 | 1306 | ADT + docetaxel + darolutamide | ADT + docetaxel + placebo | mCSPC | Overall survival | OS: HR, 0.68 (P < .001); 4-year OS: 62.7% vs 50.4% | Time to CRPC (HR, 0.36), skeletal event-free survival (HR, 0.61), time to subsequent therapy (HR, 0.39) all significantly improved | Established triplet therapy with darolutamide as category 1 option for high-volume mCSPC | N Engl J Med |
| PROSPER | Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer | 2018 | 1401 | Enzalutamide 160 mg/day + ADT | Placebo + ADT | M0 CRPC with PSADT ≤10 months | Metastasis-free survival | MFS: 36.6 vs 14.7 months (HR, 0.29; P < .0001); OS: HR, 0.73 (P = .001) | Delayed pain progression, symptom worsening, functional status decrease | Established enzalutamide for M0 CRPC with PSADT ≤10 months | N Engl J Med |
| SPARTAN | Apalutamide treatment and metastasis-free survival in prostate cancer | 2018 | 1207 | Apalutamide 240 mg/day + ADT | Placebo + ADT | M0 CRPC with PSADT ≤10 months | Metastasis-free survival | MFS: 40.5 vs 16.2 months (HR, 0.28; P < .001); final OS: 73.9 vs 59.9 months (HR, 0.78; P = .016) | QOL maintained; adverse events include rash, fracture, hypothyroidism | Established apalutamide for M0 CRPC with PSADT ≤10 months | N Engl J Med |
| ARAMIS | Darolutamide in nonmetastatic, castration-resistant prostate cancer | 2019 | 1509 | Darolutamide 600 mg twice daily + ADT | Placebo + ADT | M0 CRPC with PSADT ≤10 months | Metastasis-free survival | MFS: 40.4 vs 18.4 months (HR, 0.41; P < .001); OS: HR, 0.69 (P = .003) | Fatigue, pain in extremity, rash more common; fracture rates similar between arms | Established darolutamide for M0 CRPC with PSADT ≤10 months | N Engl J Med |
| COU-AA-301 | Abiraterone and prednisone vs placebo in patients with mCRPC post-docetaxel | 2011 | 1195 | Abiraterone 1000 mg + prednisone | Placebo + prednisone | mCRPC post-docetaxel | Overall survival | Median OS: 15.8 vs 11.2 months (HR, 0.74; P < .0001) | Time to radiographic progression, PSA decline, pain palliation all improved | First FDA approval of abiraterone for mCRPC | N Engl J Med |
| COU-AA-302 | Abiraterone in metastatic prostate cancer without previous chemotherapy | 2013 | 1088 | Abiraterone 1000 mg + prednisone | Prednisone alone | Asymptomatic or minimally symptomatic mCRPC, no prior chemotherapy | Radiographic PFS and OS | rPFS: 16.5 vs 8.3 months (HR, 0.53; P < .001); OS: 34.7 vs 30.3 months (HR, 0.81; P = .003) | Time to symptomatic deterioration, time to chemotherapy, time to pain progression, PSA responses all improved | Extended abiraterone use to pre-docetaxel mCRPC | N Engl J Med |
| AFFIRM | Increased survival with enzalutamide in prostate cancer after chemotherapy | 2012 | 1199 | Enzalutamide 160 mg/day | Placebo | mCRPC post-docetaxel | Overall survival | Median OS: 18.4 vs 13.6 months (HR, 0.63; P < .001) | PSA decline >50% (54% vs 2%), radiographic response (29% vs 4%), time to first SRE (16.7 vs 13.3 months) improved | First FDA approval of enzalutamide for mCRPC | N Engl J Med |
| PREVAIL | Enzalutamide in metastatic prostate cancer before chemotherapy | 2014 | 1717 | Enzalutamide 160 mg/day | Placebo | Chemotherapy-naive mCRPC | Radiographic PFS and OS | rPFS: 20.0 vs 5.4 months; OS: 35.3 vs 31.3 months | Time to chemotherapy, time to first SRE, PSA responses all improved | Extended enzalutamide to pre-chemotherapy mCRPC | N Engl J Med |
| PROfound | Olaparib for metastatic castration-resistant prostate cancer | 2020 | 387 | Olaparib 300 mg twice daily | Abiraterone or enzalutamide | mCRPC with HRR gene mutations, prior abiraterone or enzalutamide | Radiographic PFS | rPFS cohort A (BRCA1/2/ATM): HR, 0.34 (P < .001); entire study: HR, 0.49 (P < .001). OS cohort A: HR, 0.69 (P = .02) | Time to pain progression, time to next therapy, objective response rate improved | Established olaparib as category 1 for BRCAm mCRPC | N Engl J Med |
| TRITON3 | Rucaparib or physician's choice in metastatic prostate cancer | 2023 | 405 | Rucaparib 600 mg twice daily | Physician's choice (abiraterone, enzalutamide, or docetaxel) | mCRPC with BRCA1/2 or ATM mutation, prior ARPI, no prior chemotherapy for mCRPC | Imaging-based PFS | Median PFS: 10.2 vs 6.4 months (HR, 0.61; P < .001); BRCAm subgroup: 11.2 vs 6.4 months (HR, 0.50) | Objective response rate in BRCAm population; fatigue and nausea most common adverse events | Established rucaparib as category 1 for BRCAm mCRPC post-ARPI | N Engl J Med |
| TALAPRO-2 | Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer | 2023 | 805 | Talazoparib + enzalutamide | Placebo + enzalutamide | Untreated mCRPC | Radiographic PFS | rPFS: HR, 0.63 (P < .0001); HRRm: HR, 0.46 (P = .0003); BRCAm: HR, 0.23 (P = .0002). Final OS in HRRm: HR, 0.62 (P = .0005) | Time to symptomatic progression, time to chemotherapy; hematologic adverse events more frequent in talazoparib arm | Established talazoparib/enzalutamide for HRRm mCRPC | Lancet |
| PROpel | Abiraterone and olaparib for metastatic castration-resistant prostate cancer | 2022 | 796 | Abiraterone + olaparib | Abiraterone + placebo | mCRPC regardless of HRR mutation status | Radiographic PFS | rPFS: 24.8 vs 16.6 months (HR, 0.66; P < .001); HRRm: HR, 0.50. Final OS: HR, 0.81 (P = .054, not significant) | PSA response, time to pain progression improved; anemia, fatigue, nausea most common | Established olaparib/abiraterone for BRCAm mCRPC | Lancet Oncol |
| MAGNITUDE | Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer | 2023 | 423 | Niraparib + abiraterone | Placebo + abiraterone | mCRPC with HRR mutations, prior ARPI | Radiographic PFS | rPFS in HRRm: 16.5 vs 13.7 months (HR, 0.73; P = .022); BRCAm: 16.6 vs 10.9 months (HR, 0.53; P = .001) | Time to symptomatic progression, time to chemotherapy improved; OS analysis favorable (HR, 0.54) | Established niraparib/abiraterone for BRCAm mCRPC | J Clin Oncol |
| VISION | Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer | 2021 | 831 | Lu-177-PSMA-617 200 mCi every 6 weeks + SOC | Standard of care alone | PSMA-positive mCRPC, prior ARPI and taxane | OS and PFS | OS: 15.3 vs 11.3 months (HR, 0.62; P < .001); PFS: 8.7 vs 3.4 months (HR, 0.40; P < .001) | PSA response, quality of life; anemia, thrombocytopenia, lymphopenia more common | Established Lu-177-PSMA-617 for PSMA-positive mCRPC post-ARPI and taxane | N Engl J Med |
| PSMAfore | Lu-177-PSMA-617 versus change of ARPI therapy for taxane-naive mCRPC | 2024 | 468 | Lu-177-PSMA-617 | Change of ARPI | Taxane-naive mCRPC, prior ARPI | Radiographic PFS | rPFS: 11.6 vs 5.6 months (HR, 0.49; P < .001); OS not significantly different (crossover 57%) | Fewer grade 3-5 toxicities with Lu-177-PSMA-617 | Expanded Lu-177-PSMA-617 indication to pre-taxane mCRPC | Lancet |
| ALSYMPCA | Alpha emitter radium-223 and survival in metastatic prostate cancer | 2013 | 921 | Radium-223 monthly x 6 | Placebo | Symptomatic mCRPC with bone metastases, no visceral metastases | Overall survival | Median OS: 14.9 vs 11.3 months (HR, 0.70; P < .001); time to first SRE: 15.6 vs 9.8 months | Low grade 3-4 hematologic toxicity; improved QOL decline | Established radium-223 for symptomatic bone-metastatic mCRPC without visceral metastases | N Engl J Med |
| PEACE-3 | Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer | 2025 | 446 | Radium-223 + enzalutamide | Enzalutamide alone | Mildly symptomatic mCRPC, ARPI-naive | Radiological PFS | rPFS: HR, 0.69 (P = .0009); interim OS: HR, 0.69 (P = .0031); bone-protecting agents mandatory | Grade ≥3 AEs more common (65.6% vs 55.8%); fractures 24.3% vs 13.4% but mitigated with bone agents | Supports combination of radium-223 + enzalutamide with mandatory bone-protecting agents | Ann Oncol |
| CARD | Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer | 2019 | 255 | Cabazitaxel 25 mg/m2 | Abiraterone or enzalutamide (alternate ARPI) | mCRPC post-docetaxel and either abiraterone or enzalutamide | Radiographic PFS | rPFS: 8.0 vs 3.7 months (HR, 0.54; P < .0001); OS: 13.6 vs 11.0 months (HR, 0.64; P = .008) | Pain response, time to pain progression, time to SREs all improved with cabazitaxel | Demonstrated cabazitaxel superior to alternate ARPI after docetaxel and ARPI; supports sequential use of distinct mechanisms | N Engl J Med |
| CHAARTED | Chemohormonal therapy in metastatic hormone-sensitive prostate cancer | 2015 | 790 | ADT + docetaxel 75 mg/m2 x 6 cycles | ADT alone | mCSPC | Overall survival | OS: 57.6 vs 47.2 months (HR, 0.72; P = .002); benefit most pronounced in high-volume disease | High-volume subgroup: HR, 0.60; low-volume subgroup: HR, 1.04 (no benefit) | Established docetaxel as component of upfront therapy for high-volume mCSPC | N Engl J Med |
| TAX 327 | Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | 2004 | 1006 | Docetaxel every 3 weeks + prednisone | Mitoxantrone + prednisone | Symptomatic or rapidly progressive CRPC | Overall survival | Median OS: 18.9 vs 16.5 months (P = .009) | Pain response, PSA decline, quality of life improved | First chemotherapy to demonstrate survival benefit in mCRPC; established docetaxel as standard | N Engl J Med |
| TROPIC | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer | 2010 | 755 | Cabazitaxel 25 mg/m2 + prednisone | Mitoxantrone + prednisone | mCRPC post-docetaxel | Overall survival | OS: HR, 0.72 (P < .0001); 2.4-month survival improvement | Febrile neutropenia 7.5%, severe diarrhea 6%, anemia 11% | Established cabazitaxel for post-docetaxel mCRPC | Lancet |
| D9902B | Sipuleucel-T immunotherapy for castration-resistant prostate cancer | 2010 | 512 | Sipuleucel-T | Placebo | Minimally symptomatic or asymptomatic mCRPC | Overall survival | Median OS: 25.8 vs 21.7 months (HR, 0.78; P = .03); 22% reduction in mortality risk | Mild to moderate chills 54.1%, pyrexia 29.3%, headache 16.0% | First cancer immunotherapy to demonstrate survival benefit; established for asymptomatic mCRPC | N Engl J Med |
| EMBARK | Improved outcomes with enzalutamide in biochemically recurrent prostate cancer | 2023 | 1068 | Enzalutamide + leuprolide | Leuprolide alone or enzalutamide alone | High-risk BCR (M0 by CT/MRI/bone scan; PSADT ≤9 months) | Metastasis-free survival | Enzalutamide + leuprolide: HR, 0.42 (P < .001); enzalutamide alone: HR, 0.63 (P = .005) vs leuprolide alone | Gynecomastia 45% with enzalutamide monotherapy; nipple pain 15%; breast tenderness 14% | Established enzalutamide ± leuprolide for high-risk BCR | N Engl J Med |
| PRESTO | Intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer | 2024 | 503 | ADT + apalutamide ± abiraterone | ADT alone | High-risk BCR after RP (PSADT ≤9 months; PSA ≥0.5 ng/mL; prior RT or not RT candidate) | PSA-PFS | ADT + apalutamide: HR, 0.52 (P = .00047); ADT + apalutamide + AAP: HR, 0.48 (P = .00008) vs ADT alone | No significant further benefit adding AAP to apalutamide; hypertension most common grade ≥3 AE | Established apalutamide + ADT as category 2B option for high-risk BCR after maximal pelvic therapy | J Clin Oncol |
| AMPLITUDE | Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer | 2025 | 696 | ADT + niraparib/abiraterone | ADT + abiraterone | HRR-deficient mCSPC (78% high-volume, 87% synchronous) | Radiographic PFS | rPFS in BRCAm: not reached vs 26.0 months (HR, 0.52; P < .0001); full ITT: HR, 0.63 (P = 0.0001) | Grade 3/4 AEs: 75% vs 59%; treatment-related deaths: 14 vs 7; anemia 29.1% vs 4.6% | Established niraparib/abiraterone as option for BRCA2m mCSPC | Nat Med |
| ORIOLE | Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer | 2020 | 54 | MDRT | Observation | Previously treated, 1-3 metastases by conventional imaging | PFS | Median PFS: not reached vs 5.8 months (HR, 0.30; P = .002) | Treatment well tolerated; combined analysis with STOMP demonstrated pooled HR, 0.44 (P < .001) | Supports MDT for metachronous oligorecurrent CSPC | JAMA Oncol |
| SABR-COMET | Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers | 2020 | 99 | MDRT to all sites | Palliative systemic therapy | Oligometastatic (1-5 metastases) breast, lung, colorectal, prostate cancers | OS | 5-year OS: 42.3% vs 17.7% (P = .006) in total population | Including 16 prostate cancer patients (14 randomized to MDRT); post-hoc analysis excluding prostate patients showed trend in favor of MDRT | Supports MDT approach in oligometastatic disease | J Clin Oncol |
| ASCENDE-RT | Androgen suppression combined with elective nodal and dose escalated radiation therapy | 2017 | 398 | EBRT + LDR brachytherapy boost + 12 months ADT | EBRT boost to 78 Gy + 12 months ADT | Intermediate- or high-risk prostate cancer | Biochemical PFS | bPFS: 86% vs 75% at 7 years (P < .001); grade 3 GU toxicity: 18.4% vs 5.2% | Higher toxicity with brachytherapy boost; no OS benefit demonstrated | Supports brachytherapy boost for dose escalation with careful patient selection | Int J Radiat Oncol Biol Phys |
| HYPO-RT-PC | Ultrahypofractionated versus conventionally fractionated radiotherapy for prostate cancer | 2019 | 1200 | 42.7 Gy in 7 fractions | 78.0 Gy in 39 fractions | Intermediate- and high-risk prostate cancer | Failure-free survival | Noninferior for FFS; no significant difference in toxicity | Patient convenience and reduced treatment burden | Established ultra-hypofractionation as noninferior to conventional fractionation | Lancet |
| PACE-B | Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer | 2024 | 874 | SBRT (5 fractions) | Moderate hypofractionation (62 Gy in 20 fractions) | Low- and intermediate-risk prostate cancer | Freedom from biochemical/clinical failure | Noninferior for tumor control; generally similar safety profiles | Patient convenience; SBRT requires precision treatment setup | Established SBRT as noninferior to moderate hypofractionation for low- and intermediate-risk disease | N Engl J Med |
| RADICALS-RT | Timing of radiotherapy after radical prostatectomy | 2024 | 1396 | Immediate adjuvant RT | Monitoring with policy to treat at PSA 0.1 ng/mL or rising | Adverse features after RP | Biochemical PFS | No difference in 5-year bPFS; no difference in OS; urinary incontinence and urethral strictures more frequent with adjuvant | Freedom from distant metastasis at 10 years: 93% vs 90% (P = .095) | Supports early secondary RT over immediate adjuvant RT for most patients | Ann Oncol |
| ProtecT | Prostate testing for cancer and treatment | 2016 | 1643 | Active monitoring, radical prostatectomy, or radiotherapy | Three-way randomization | Localized prostate cancer | Prostate cancer mortality | No significant difference in prostate cancer mortality at 10-15 years (P = .48); 12.2% increase in disease progression and 3.4% increase in metastases/death in active monitoring group | Surgery associated with greater urinary incontinence and impotence; RT associated with slight decrease in bowel function; 70% of monitoring arm received treatment by 15 years | Demonstrated safety of conservative management for low-risk disease; highlighted importance of risk-adapted treatment selection | N Engl J Med |
Clinical PearlsClick to collapse
- Pearl 1: Approximately 50% of patients eligible for active surveillance may safely avoid treatment for at least 10 years, but approximately 70% will require treatment by 15 years, highlighting the importance of long-term follow-up compliance.
- Pearl 2: The 22-gene genomic classifier (Decipher) has demonstrated independent prognostic value for distant metastasis, prostate cancer-specific mortality, and overall survival across multiple phase 3 randomized trials, and should be used when it has the potential to change management.
- Pearl 3: ADT monotherapy should not be used as primary treatment for clinically localized prostate cancer unless there is a clear contraindication to definitive local therapy; combination therapy is strongly recommended for metastatic castration-sensitive disease.
- Pearl 4: PSMA-PET/CT has superior sensitivity and specificity compared to conventional imaging for detecting micrometastatic disease, but expert interpretation is essential to avoid false-positive classification that could lead to inappropriate treatment escalation.
- Pearl 5: Intermittent ADT can be considered to reduce toxicity in appropriate patients with metastatic disease, particularly those with M0 recurrent disease, though close monitoring during off-treatment periods is essential.
- Pearl 6: For patients with BRCA2-mutated metastatic castration-sensitive prostate cancer, niraparib/abiraterone is a new option, but benefit in low-volume disease is controversial due to limited data in this population.
- Pearl 7: Biopsy of accessible metastatic lesions should be performed in all patients with mCRPC to identify small cell/neuroendocrine histology and perform molecular testing, as this fundamentally changes the treatment approach.
- Pearl 8: Black individuals with prostate cancer have 67% higher incidence and 2-4x higher mortality rates than other racial/ethnic groups, but outcomes are equivalent when receiving guideline-concordant care, underscoring the critical importance of equitable treatment access.
Special SituationsClick to collapse
Active Surveillance in Low-Risk Disease
Active Surveillance in Favorable Intermediate-Risk Disease
High-Risk Biochemical Recurrence (BCR2)
Metastasis-Directed Therapy for Oligometastatic CSPC
PARP Inhibitor Therapy in BRCAm mCRPC
Lu-177-PSMA-617 in mCRPC
Small Cell/Neuroendocrine Prostate Cancer
Cardiovascular Disease Risk with ADT/ARPIs
Triple Therapy for High-Volume mCSPC
Racial and Ethnic Disparities
Guidelines ResourcesClick to collapse
NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer
NCCN Guidelines for Prostate Cancer Early Detection
NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate
NCCN Guidelines for Survivorship
NCCN Guidelines for Hematopoietic Growth Factors
NCCN Guidelines for Distress Management
NCCN Guidelines for Older Adult Oncology
NCCN Guidelines for Small Cell Lung Cancer
NCCN Guidelines for Management of Immunotherapy-Related Toxicities
The Clinician's Guide to Prevention and Treatment of Osteoporosis
ISCD Official Positions
ACR Appropriateness Criteria
AJCC Cancer Staging Manual, Eighth Edition
Protective FactorsClick to collapse
- 5-alpha reductase inhibitors (e.g., finasteride, dutasteride) have been shown in large randomized trials to reduce the risk of low-grade prostate cancer by about 25%, but the absolute risk reduction and potential for diagnosing higher-grade disease need careful consideration [18].
- Regular vigorous exercise may be associated with a modestly reduced risk of aggressive prostate cancer, though evidence is not conclusive.